NASDAQ:REPL Replimune Group (REPL) Stock Price, News & Analysis $7.49 +0.03 (+0.40%) Closing price 04:00 PM EasternExtended Trading$7.50 +0.01 (+0.20%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Replimune Group Stock (NASDAQ:REPL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Replimune Group alerts:Sign Up Key Stats Today's Range$6.85▼$7.7850-Day Range$7.46▼$14.3152-Week Range$4.92▼$17.00Volume942,260 shsAverage Volume862,878 shsMarket Capitalization$576.84 millionP/E RatioN/ADividend YieldN/APrice Target$19.43Consensus RatingBuy Company OverviewReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Read More… Remove Ads Replimune Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreREPL MarketRank™: Replimune Group scored higher than 65% of companies evaluated by MarketBeat, and ranked 263rd out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageReplimune Group has only been the subject of 3 research reports in the past 90 days.Read more about Replimune Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Replimune Group are expected to grow in the coming year, from ($2.97) to ($2.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Replimune Group's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.60% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Replimune Group has recently increased by 4.49%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.28 Percentage of Shares Shorted13.60% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Replimune Group has recently increased by 4.49%, indicating that investor sentiment is decreasing. News and Social Media1.3 / 5News Sentiment0.37 News SentimentReplimune Group has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Replimune Group this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for REPL on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.80% of the stock of Replimune Group is held by insiders.Percentage Held by Institutions92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Replimune Group's insider trading history. Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address REPL Stock News HeadlinesReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | globenewswire.comReplimune price target raised to $18 from $16 at JPMorganFebruary 26, 2025 | markets.businessinsider.comFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money isn't legally yours. Now, think your savings are safe? Think again.April 7, 2025 | Priority Gold (Ad)Replimune price target raised to $22 from $21 at H.C. WainwrightFebruary 13, 2025 | markets.businessinsider.comNavigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global RisksFebruary 13, 2025 | msn.comReplimune stock target raised to $22 at H.C. WainwrightFebruary 13, 2025 | msn.comBarclays Keeps Their Buy Rating on Replimune Group (REPL)February 13, 2025 | markets.businessinsider.comReplimune price target raised to $19 from $16 at WedbushFebruary 12, 2025 | markets.businessinsider.comSee More Headlines REPL Stock Analysis - Frequently Asked Questions How have REPL shares performed this year? Replimune Group's stock was trading at $12.11 on January 1st, 2025. Since then, REPL stock has decreased by 38.2% and is now trading at $7.49. View the best growth stocks for 2025 here. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) issued its quarterly earnings data on Wednesday, February, 12th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.09. When did Replimune Group IPO? Replimune Group (REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are Replimune Group's major shareholders? Top institutional shareholders of Replimune Group include GAMMA Investing LLC (0.01%). Insiders that own company stock include Robert Coffin, Philip Astley-Sparke, Colin Love, Pamela Esposito, Tanya Lewis, Konstantinos Xynos, Christopher Sarchi and Andrew Schwendenman. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Replimune Group investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD). Company Calendar Last Earnings2/12/2025Today4/07/2025Next Earnings (Estimated)5/15/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:REPL CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees210Year Founded2015Price Target and Rating Average Stock Price Target$19.43 High Stock Price Target$27.00 Low Stock Price Target$16.00 Potential Upside/Downside+159.4%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-215,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.84% Return on Assets-42.97% Debt Debt-to-Equity Ratio0.14 Current Ratio11.43 Quick Ratio11.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.26 per share Price / Book1.20Miscellaneous Outstanding Shares77,015,000Free Float70,238,000Market Cap$576.84 million OptionableOptionable Beta1.26 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:REPL) was last updated on 4/7/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.